<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; biomarkers</title>
	<atom:link href="http://www.tapanray.in/tag/biomarkers/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>The Stakeholder-Mix Has Changed, But Pharma Marketing Has Not</title>
		<link>http://www.tapanray.in/the-stakeholder-mix-has-changed-but-pharma-marketing-has-not/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-stakeholder-mix-has-changed-but-pharma-marketing-has-not</link>
		<comments>http://www.tapanray.in/the-stakeholder-mix-has-changed-but-pharma-marketing-has-not/#comments</comments>
		<pubDate>Mon, 13 Jun 2016 00:00:25 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[biomarkers]]></category>
		<category><![CDATA[captains]]></category>
		<category><![CDATA[category]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[Drucker]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Game]]></category>
		<category><![CDATA[George]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[inclusive]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[mindset]]></category>
		<category><![CDATA[multi-stakeholder]]></category>
		<category><![CDATA[multichannel]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[Old]]></category>
		<category><![CDATA[paradigm]]></category>
		<category><![CDATA[personalized]]></category>
		<category><![CDATA[Peter]]></category>
		<category><![CDATA[pipeline]]></category>
		<category><![CDATA[plan]]></category>
		<category><![CDATA[President]]></category>
		<category><![CDATA[profit]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[recasting]]></category>
		<category><![CDATA[Self]]></category>
		<category><![CDATA[serving]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7670</guid>
		<description><![CDATA[“We try never to forget that medicine is for the people. It is not for profit. Profits follow, and if we have remembered that, they never fail to appear.” In 1952, George Wilhelm Herman Emanuel Merck, the then President of &#8230; <a href="http://www.tapanray.in/the-stakeholder-mix-has-changed-but-pharma-marketing-has-not/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-stakeholder-mix-has-changed-but-pharma-marketing-has-not/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>A Potential Game Changer For Pharma R&amp;D</title>
		<link>http://www.tapanray.in/a-potential-game-changer-for-pharma-rd/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=a-potential-game-changer-for-pharma-rd</link>
		<comments>http://www.tapanray.in/a-potential-game-changer-for-pharma-rd/#comments</comments>
		<pubDate>Mon, 10 Feb 2014 00:00:35 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Abdul]]></category>
		<category><![CDATA[Alzheimer's]]></category>
		<category><![CDATA[AMP]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[biomarkers]]></category>
		<category><![CDATA[Changer]]></category>
		<category><![CDATA[chris]]></category>
		<category><![CDATA[cliff]]></category>
		<category><![CDATA[Collaborative]]></category>
		<category><![CDATA[CSIR]]></category>
		<category><![CDATA[Game]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[kalam]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[NIH]]></category>
		<category><![CDATA[OHE]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[OSDD]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[potential]]></category>
		<category><![CDATA[PPP]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[source]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[UK]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[viehbacher]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=4974</guid>
		<description><![CDATA[The ghost of ‘Patent Cliff’ has been haunting the ‘Big Pharma’ since quite some time. This situation has been further aggravated by cost containment pressures of various Governments both in the developed and the emerging markets together with contentious issues &#8230; <a href="http://www.tapanray.in/a-potential-game-changer-for-pharma-rd/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/a-potential-game-changer-for-pharma-rd/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
